A tumor-cell MHC-II program is associated with checkpoint-blockade outcomes across stages of bladder cancer
Joaquim Bellmunt B, Yingtian Xie, Miguel Gómez Muñoz, Shweta Kukreja, Sarah Walker, Ruiyang He, Rong Li, Xintao Qiu, Tao Zhang, Paloma Rodriguez, Diego García González, Ilana Bensussen Epstein, Julia Parera, Nuria Juanpere-Rodero, Marta Lorenzo, , Henry W. Long
This study identifies a tumor-cell MHC-II program linked to immunotherapy outcomes in bladder cancer across different stages and treatment settings.
bioRxiv · Sep 22, 2026 · PreprintCancer Biology